RemeGen Co., Ltd.
Quick facts
Marketed products
- Placebo plus standard therapy
Placebo plus standard therapy provides no active pharmacological intervention beyond the standard treatment already being administered. - Telitacicept Freeze-dried powder Injection 80mg
Phase 3 pipeline
- Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine · Oncology
This combination therapy targets HER2-positive gastric cancer through antibody-drug conjugate-mediated tumor cell killing, immune checkpoint inhibition, and chemotherapy-induced DNA damage. - Pertuzumab Injection · Oncology
Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling. - RC-28E · Oncology
RC-28E is a monoclonal antibody targeting PD-1. - RC148 plus Carboplatin and Paclitaxel · Oncology
RC148 is a PD-L1 inhibitor combined with standard chemotherapy (carboplatin and paclitaxel) to enhance anti-tumor immune response while providing cytotoxic chemotherapy. - RC28-E · Oncology
RC28-E is a monoclonal antibody targeting PD-1. - RC48-ADC · Oncology
RC48-ADC is an antibody-drug conjugate that targets HER2-positive cancer cells by delivering cytotoxic payload directly to tumor cells expressing the HER2 receptor. - Tislelizumab plus Carboplatin and Paclitaxel · Oncology
Tislelizumab is a monoclonal antibody that targets PD-1, while carboplatin and paclitaxel are chemotherapeutic agents that interfere with DNA replication and cell division.
Phase 2 pipeline
- Albumin-bound Paclitaxone · Oncology
Albumin binding enhances the solubility of paclitaxel, allowing for higher doses to be administered. - Disitamab Vedotin for injection · Oncology
Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the epidermal growth factor receptor (EGFR) and delivers a microtubule inhibitor to cancer cells. - Disitamab Vedotin Injection · Oncology
Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the Trop-2 receptor. - Disitamab Vedotin Injection （12 weeks）
- Disitamab Vedotin Injection （18 weeks） · Oncology
Anti-CD6 monoclonal antibody - Furmonertinib Mesilate Tablets Monotherapy
- intravitreal injection of RC28-E
- RC108
- RC148
- RC48-ADC in Combination with gemcitabine
- RC88
- Sequential CTX
- Sequential Epirubicin
- Toripalimab （12weeks）
- Toripalimab （18weeks）
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about RemeGen Co., Ltd.
What are RemeGen Co., Ltd.'s marketed drugs?
Top marketed products include Placebo plus standard therapy, Telitacicept Freeze-dried powder Injection 80mg.
What is RemeGen Co., Ltd.'s pipeline?
RemeGen Co., Ltd. has 7 drugs in Phase 3, 15 in Phase 2, 5 in Phase 1. Late-stage candidates include Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine, Pertuzumab Injection, RC-28E, RC148 plus Carboplatin and Paclitaxel.